CLINICAL TRIALS PROFILE FOR CHLORTHALIDONE
✉ Email this page to a colleague
All Clinical Trials for chlorthalidone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000499 ↗ | Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) | Completed | National Institute on Aging (NIA) | Phase 2 | 1980-09-01 | The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints. |
| NCT00000499 ↗ | Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1980-09-01 | The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints. |
| NCT00000513 ↗ | Trial of Antihypertensive Intervention Management | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1984-04-01 | The objective of the Trial of Antihypertensive Intervention Management (TAIM) was to determine the efficacy of dietary management and/or drug therapy, namely thiazide-like diuretics or a beta-blocker, in the control of mild hypertension. Additionally, the Continuation of the Trial of Antihypertensive Intervention Management (COTAIM) tested the effects of long-term weight reduction, and sodium/potassium changes added to weight reduction, as well as the original drug treatment, on the failure rate of blood pressure control. |
| NCT00000514 ↗ | Systolic Hypertension in the Elderly Program (SHEP) | Completed | National Institute on Aging (NIA) | Phase 3 | 1984-06-01 | The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for chlorthalidone
Condition Name
Clinical Trial Locations for chlorthalidone
Trials by Country
Clinical Trial Progress for chlorthalidone
Clinical Trial Phase
Clinical Trial Sponsors for chlorthalidone
Sponsor Name
